**N-Acetyl-Cysteine Decreases the Matrix-Degrading Capacity of Macrophage-Derived Foam Cells**  
**New Target for Antioxidant Therapy?**

Zorina S. Galis, PhD; Kazuhiko Asanuma, MD; Denis Godin, PhD; Xiaoping Meng, MD

**Background**—Atherosclerotic plaque destabilization triggers clinical cardiovascular disease and thus represents an attractive therapeutic target. Weakening of tissue through the action of matrix-degrading enzymes, called matrix metalloproteinases (MMPs), released by resident macrophages was previously implicated in unstable vascular syndromes.

**Methods and Results**—We used a hypercholesterolemic rabbit model of atherosclerosis to investigate the gelatinolytic activity associated with macrophage-derived foam cells (FCs). Gelatinolytic activity and expression of MMP-9 but not of MMP-2 cosegregated with macrophage FCs in aortic lesions. Macrophage-derived gelatinases were further investigated in vitro. MMP-9 was identified as the main macrophage-derived gelatinase in cells isolated from aortic lesions and from granuloma induced in the same rabbits to increase cell yield. Importantly, detection of activated MMP-9 in the FC culture medium supports the notion that these cells can independently initiate processing of secreted MMP zymogens to active enzymes. We further examined whether FC gelatinolytic activity is dependent on the presence of reactive oxygen species (ROS). We found that treatment (1 to 5 days) with 1 to 10 mmol/L N-acetyl-L-cysteine (NAC), an ROS scavenger, decreased not only gelatinolytic activity but also gelatinase expression by FCs. Similarly, NAC treatment of explanted lesions abolished in situ gelatinolytic activity and MMP-9 expression.

**Conclusions**—Macrophage FCs are an abundant source of gelatinolytic activity that can be inhibited in vitro and in situ by NAC. This newly described action of antioxidant therapy might prove useful to inhibit matrix degradation and to improve vascular stability.  
(Circulation. 1998;97:2445-2453.)

**Key Words:** atherosclerosis ■ metalloproteinases ■ free radicals ■ antioxidants

Macrophage-derived FCs, which figure prominently in areas of atherosclerotic plaques prone to rupture, are a likely source of plaque instability. Many recent studies focusing on various aspects of the active macrophage FC involvement in the weakening of the vascular matrix scaffold suggest that it is a major factor determining plaque vulnerability. Activated macrophages release cytokines, which increase the repertoire of matrix-degrading enzymes, called MMPs, secreted in vitro by vascular cells and produce their own MMPs. Furthermore, we and others have shown that macrophage-derived FCs resident in human and experimental atherosclerotic lesions are also associated with matrix-degrading activity due to active MMPs. To digest matrix components, however, latent cell-secreted MMPs require posttranslational processing to active forms, a step acting as a key regulatory mechanism of matrix degradation by MMPs. In our search for MMP activation mechanisms relevant to atherosclerosis, we recently found that ROSs can trigger activation of MMP precursors released by vascular SMCs. Similar ROSs are produced by macrophage-derived FCs; thus, in addition to modulating vascular MMP gene transcription via release of stimulatory cytokines, these cells may regulate MMP enzymatic activation via release of ROSs. In addition, macrophage-derived FCs most likely contribute with their own MMPs to matrix degradation. Certain conditions enhance production of MMPs by monocytic cells and cell lines, and the intracellular lipid accumulation characteristic of monocyte-derived macrophages residing in atheroma could be one of them. We found previously that the macrophage-derived FCs isolated from aortic lesions of hypercholesterolemic rabbits secrete in vitro precursors of the inducible MMPs interstitial collagenase and stromelysin. However, we did not detect generation of their active forms, the only ones capable of matrix degradation. We also did not investigate the expression of the macrophage-derived gelatinases MMP-9 and MMP-2. These MMPs, specialized in digestion of basement membrane collagens and elastin, have since been implicated in weakening of vascular tissue in unstable coronary syndromes and in aortic aneurysms. Thus, in the present study, we sought to characterize gelati-
nase production by in vivo differentiated macrophage FCs, which to the best of our knowledge has not yet been investigated. We also explored the hypothesis that gelatinase activity in atheroma areas rich in macrophage-derived FCs is ROS-dependent and thus inhibitable by ROS scavengers. For this purpose, we used an experimental hypercholesterolemic rabbit model that develops macrophage FC–rich aortic lesions and allows isolation of in vivo differentiated macrophage FCs for in vitro studies.

Methods

Animal Model of Atherosclerosis

Experimental atherosclerotic lesions were induced in the double-injury rabbit model, in which aortic intimal lesions are rich in lipid-laden macrophages. We induced aortic lesions in New Zealand White rabbits (n=8), as previously described in detail, by balloon angioplasty 1 week after initiating a hypercholesterolemic diet (0.5% cholesterol and 4.5% coconut oil added to Purina chow). The diet was maintained for the following 8 weeks. Three weeks before the animals were killed, subcutaneous granulomas were induced in the same rabbits by implantation of 2 or 3 sterile polyurethane sponges (Baxter Scientific) per animal under the dorsal skin. A similar procedure was used simultaneously to induce subcutaneous granuloma formation in normocholesterolemic New Zealand White rabbits on regular Purina chow. All animals were euthanized with 100 mg/mL pentobarbital. Aortas were harvested in O.C.T. compound (Miles) to identify macrophages (anti–MMP-9 monoclonal antibodies (Oncogene Science), recognizing both the latent and active forms, was followed by incubation with secondary antibodies coupled to horseradish peroxidase and development of a chemiluminescent reaction (ECL kit from Amersham International). Signals (positive bands) were quantified and analyzed as described above.

Histological Characterization of Aortic Tissue and Isolated Cells

Immunostaining was performed on frozen tissue specimens embedded in O.C.T. compound (Miles) to identify macrophages (anti–RAM-11, Dako Corp) and to detect MMP-9 and MMP-2 (Oncogene). Staining was developed with the LSAB staining kit (Dako), and sections were counterstained with Gill’s hematoxylin (Sigma). Isolated cells were stained by single or double immunofluorescence using species-specific secondary antibodies coupled to fluorochromes (FITC or Texas Red, Jackson ImmunoResearch). Nuclei were counterstained for 2 minutes with 0.5 µg/mL bisbenzamide (Calibiochem). Intracellular lipid accumulation was revealed by staining of cells with 5 µg/mL Nile red (Molecular Probes).

In Situ Zymography

In situ gelatinolytic activity was detected in frozen aortic tissue specimens as previously described, with gelatin coupled to a green fluorochrome. Briefly, tissues were processes for obtaining unfixed frozen sections, which were placed on microscope slides previously coated with fluorescent gelatin. The specimens were then incubated at 37°C for 2 days and examined with a Zeiss fluorescence microscope to reveal areas of active lysis of the gelatin substrate.

Results

Gelatinolytic Activity Is Associated With Increased MMP-9 Expression and Macrophage-Derived FCs in Experimental Atheroma

Neointimal lesions developed in the double-injury model of atherosclerosis were composed predominantly of macrophage-derived FCs (Figure 1) identified by immunohisto-
chemistry with a macrophage-specific antibody. The gelatinolytic activity, examined by in situ zymography, was restricted to the macrophage-rich intimal area. Immunostaining for the two possible sources of gelatinolytic activity, MMP-2 (gelatinase A) and MMP-9 (gelatinase B), showed that expression of MMP-9 was specifically associated with the neointimal lesion, whereas MMP-2 staining was diffuse. This observation suggested that the macrophage-derived gelatinolytic activity was due mainly to the presence of macrophage-derived MMP-9.

**Characterization of Lipid-Laden Macrophages**

Further experiments were performed to confirm that the lipid-laden macrophage was the source of MMP-9 and gelatinolytic activity. However, to further investigate expression and activation of gelatinases in culture, we had to find an alternative source of macrophage-derived FCs, the yield of aortic FCs being very limited ($3 \times 10^5$ to $10^6$ cells per aorta). We therefore produced and isolated in vivo differentiated macrophage-derived FCs from subcutaneous granulomas of hypercholesterolemic rabbits. To be able to assess possible differences associated with the FC phenotype, we also produced and studied, in parallel, non–lipid-laden macrophages by implanting subcutaneous sponges in normocholesterolemic rabbits. Isolated cells were positively identified as being of macrophage origin by immunofluorescence with the RAM-11 antibody (Figure 2) and were used for the in vitro experiments. Macrophage purity and viability were >98%.

**Figure 1.** Experimental atheroma in aorta of hypercholesterolemic rabbits. Detection of macrophages, gelatinolytic activity, and expression of gelatinases MMP-2 and MMP-9. Top four panels illustrate consecutive sections of lesions in abdominal aorta; bottom four panels, in thoracic aorta. Top, Staining with cell-specific antibody (RAM-11) identifies numerous macrophages in intimal region. Same region contains gelatinolytic activity, as shown by processing of a consecutive section by in situ zymography (gelatinolytic activity is indicated by disappearance of green fluorescent gelatin substrate used to coat microscope slide). Immunostaining for MMP-2 and MMP-9 gelatinases shows colocalization of macrophage accumulations with MMP-9 expression but not with MMP-2. Bottom, Macrophages, MMP-9 expression, and gelatinolytic activity colocalize in a thoracic aorta lesion. Control specimens were processed without primary antibody (Ab). Bars = 100 μm.
Nile red staining confirmed intracellular lipid accumulation in macrophages from hypercholesterolemic rabbits. Granuloma FC yield was an order of magnitude higher than aorta (2×10^7 to 3×10^7 per rabbit). These FCs produced MMP-3 (Figure 2), similar to macrophage-derived FCs isolated from aortic lesions.14

Macrophage-Derived FCs Release and Activate MMP-9

Analysis of gelatinolytic activity released in culture by different segments of atherosclerotic rabbit aorta by SDS-PAGE zymography showed that the aortic arch consistently produced the highest level of total gelatinolytic activity. The activity released by thoracic aorta was also higher than that of abdominal aorta (Figure 3). The gradual increase in gelatinolytic activity paralleled the extent of macrophage-rich lesions. Migration of higher-molecular-weight gelatinolytic activity was consistent with the presence of MMP-9, whereas gelatinolytic activity running at lower molecular weight was most likely due to MMP-2, the main MMP produced by vascular SMCs. Analysis of gelatinolytic activity released in culture by isolated aortic or granulomatous FCs showed that these cells produce copious amounts of the gelatinolytic activity associated with MMP-9. Because gelatinolytic profiles were identical for the FCs isolated from either source, we used granuloma macrophages for further in vitro experiments. Both lipid-laden and non–lipid-laden macrophages were maintained in culture up to 5 days.

Effect of NAC on Protein Expression and Activity of Macrophage-Derived MMP-9

Because our recent experiments showed that ROSs may function as activators of SMC-derived latent gelatinases,13 we hypothesized that activation of FC-derived pro–MMP-9 may be related to concomitant production of ROSs. To test ROS contribution, we treated macrophages with NAC, an ROS scavenger. Gelatinolytic activity in the culture media of untreated and NAC-treated cells was analyzed by SDS-PAGE zymography. We found that 24 hours of treatment with NAC reduced both the gelatinolytic activity consistent with migra-
tion of the MMP-9 zymogen and that of the faster band migrating at the expected position for active MMP-9 (Figure 4). To confirm the identity of MMP-9 and to further assess effects of treatment, we also analyzed the effect of NAC on MMP-9 protein level by immunoblotting (Figure 5). Comparing non–lipid-laden and lipid-laden macrophages, we identified the MMP-9 precursor in culture media conditioned by either macrophage population. Interestingly, only the culture media conditioned by lipid-laden macrophages contained the fully activated MMP-9, migrating around 66 kDa as previously reported.\(^{19,20}\) The same anti–MMP-9 antibodies did not recognize SMC-derived MMP-2, which has a similar apparent molecular weight (not shown), confirming that this faster band was indeed generated through processing of latent MMP-9. Culture media from macrophage FCs treated with 10 mmol/L NAC for 48 hours had significantly lower levels of the precursor and active forms of MMP-9. NAC treatment also inhibited expression of the MMP-9 precursor by non–lipid-laden macrophages. We also confirmed that the decreased gelatinase production was not due to a cytotoxic effect of NAC. Viability tests performed at the end of each experiment showed that after 5 days in culture, FC viability was 79.3±6.8% live cells in untreated versus 72.4±11.9% live cells treated with 10 mmol/L NAC (\(n=8, P=\text{NS}\)).

**NAC Reduces the Gelatinolytic Activity and In Situ Expression of MMP-9 in Experimental Atherosclerotic Lesions**

The results obtained with cultured macrophage-derived FCs and non–lipid-laden macrophages suggested the possibility of reducing production of active gelatinase by resident macrophages through NAC treatment. This effect was tested by incubating segments of atherosclerotic rabbit aorta with NAC in organ culture conditions. We found that the NAC treatment abolished the gelatinolytic activity released by aortic tissue and significantly decreased the level of MMP-9 protein detected by Western blotting (Figure 6). The fact that the effect of NAC was not restricted to inhibition of gelatinolytic activity but rather also affected FC MMP-9 expression was confirmed by the disappearance of MMP-9 immunopositive staining in the FC-rich lesions maintained in culture with NAC (Figure 7). This effect was specific to the signal associated with the presence of MMP-9, since it did not affect expression of macrophage markers also detected by immunostaining. In addition, detection of MMP-9 was not affected in paired untreated specimens that were maintained in culture and processed simultaneously (Figure 7). Thus, lack of MMP-9 detection in lesions after treatment with NAC suggests that the action of NAC is not restricted to inhibition of MMP-9 activity or cellular secretion but rather also involves suppression of macrophage MMP-9 synthesis.

**Discussion**

Recently, the action of MMPs has emerged as an important component of the natural history of atherosclerosis\(^8,11,21\) and of the vascular response to injury.\(^{22-24}\) Macrophage-derived FCs associate clinically with unstable human plaques\(^1-3\) and microscopically with vulnerable areas and active MMPs\(^8\) and thus may be responsible for compromising vascular tissue integrity through matrix degradation. Macrophages are also thought to be a major source of the redox stress that characterizes atherosclerotic vessels.\(^{25-27}\) In the present study, we investigated production and activation of gelatinases produced by macrophage FCs of hypercholesterolemic rabbits, a good model for study of macrophage-derived FCs resident in human atheroma. We also hypothesized that macrophage-derived FCs have a built-in redox-dependent mechanism leading to activation of their own MMP zymogens. We found that gelatinolytic activity in rabbit atherosclerotic lesions is restricted to the macrophage-rich areas and colocalizes with expression of MMP-9. Study of isolated cells

---

\(24\) h  \(48\) h  \(4\) days

![MMP-9 Zymography](image)

**Figure 4.** NAC reduces gelatinolytic activity in culture media of macrophage-derived FCs. A, SDS-PAGE gelatin zymography. Culture media were harvested from macrophage FCs maintained in culture for up to 4 days in absence (−) or presence (+) of 10 mmol/L NAC. Incubation of FCs with NAC reduces gelatinolytic activity running at both high apparent molecular weight (MW) and low MW. Migration of gelatinolytic activity with high MW is consistent with pro–MMP-9, while faster gelatinolytic band is consistent with both processed (active) form of MMP-9 and pro–MMP-2. B, Densitometric analysis of gelatinolytic activity (high and low MW) released by FCs shows a significant reduction after 48 hours of treatment with 10 mmol/L NAC. Values were normalized to matched untreated control ±SEM (\(n=4\) independent experiments, \(^*P<0.05\)).
confirmed that macrophage-derived FCs were a major source of MMP-9 and detected the presence of active MMP-9. As mentioned, increases in MMP-9 activity were previously reported in vascular disease and a variety of other pathological situations with an inflammatory component, such as rheumatoid arthritis, as well as metastasis. To obtain sufficient material for meaningful in vitro studies with macrophage-derived FCs, we also induced formation of these cells in vivo in granulomas of hypercholesterolemic rabbits. Implantation of subcutaneous sponges triggers formation of granulomas whose macrophages accumulate lipid in hypercholesterolemic conditions. These macrophage-derived FCs from subcutaneous granulomas had the same MMP profile as the aortic FCs.

Observations made on isolated macrophages in culture showed the presence of active gelatinase, although all MMPs known so far are reportedly secreted by cells as zymogens only. This in vitro observation supports the notion that MMP-9 activation can occur independently of the classic plasmin-mediated pathway. The possibility that macrophage gelatinolytic activity is redox-dependent is suggested by our previous studies showing activation of gelatinase zymogens by ROSs known to be produced by macrophage FCs, as well as by our present detection of active MMP-9 in an isolated cell system along with inhibition of macrophage-derived gelatinolytic activity by treatment with NAC, an ROS scavenger. Activated macrophages, especially those of atherosclerotic lesions, are a major source of ROSs; thus, such an activation mechanism would result in activation of MMP zymogens secreted by the macrophages themselves as well as by the neighboring cells. However, our observations do not exclude the possibility that activation of MMP-9 might occur through other cell-dependent mechanisms, including the action of a group of cell membrane molecules called MT-MMPs. It was reported that these molecules activate the zymogens of MMP-2 and MMP-13, but it is not yet known whether monocytes/macrophages express MT-MMPs and whether pro–MMP-9, the gelatinase whose activity was investigated in this study, is a substrate for MT-MMPs.

NAC is widely used as an antioxidant on the basis of its capacity to scavenge ROSs; however, its inhibitory effect on gelatinolytic activity might also involve a direct interaction with the enzyme. Although further biochemical studies will be necessary to differentiate between these two possible components of gelatinase inhibition, the capacity of NAC to inhibit gelatinolysis that we found is unquestionable. This is important because regulation of gelatinolytic activity ultimately determines the level of matrix degradation by vascular gelatinases. However, our results suggesting that NAC may also affect prior events in the pathway leading to secretion of...
endothelial cells and SMCs. MMP-9 induction may require cooperation between AP-1, NF-κB, or SP-1-responsive elements. Conversely, monocyte/macrophages constitutively express pro–MMP-9, but its expression was shown to be enhanced by cellular differentiation, concanavalin A, or LPS stimulation. Interestingly, the effects of LPS, cytokines, and phorbol esters may occur via generation of ROS intermediates. In transformed cells, multiple pathways leading to activation of redox-sensitive transcription factors, such as NF-κB, SP-1, Ets, and AP-1, have been shown to increase expression of MMP-9. These additional considerations and the present results support the hypothesis that MMP-9 gene expression could be redox-regulated. As they become available, further experiments using species-specific molecular probes will be performed to confirm our observations at the messenger RNA level.

Beneficial cardiovascular effects of various antioxidant therapies were reported in human and experimental atherosclerosis or restenosis, and efforts to understand its mechanism of action are under way. Treatments with probucol and vitamins E and C have been shown to reduce intimal lesions after balloon injury in hypercholesterolemic animals. In addition to decreasing the lipid content and lesion area, antioxidants also appear to alter lesion cellularity, reducing primarily the monocyte-macrophage content. In addition to potentially reducing the extracellular effects of ROSs (eg, oxidative modification of lipoproteins and activation of MMPs), scavenging ROSs may prevent or diminish intracellular activation of redox-sensitive genes. Recently published results showed that after dietary supplementation with α-tocopherol, peripheral blood monocytes harvested from healthy volunteers produced fewer ROSs and interleukin-1 and displayed decreased adherence to endothelium when stimulated with LPS. Also, NAC was found to inhibit vascular cell adhesion molecule-1 expression in vitro and in vivo. Abatement of these effects of oxidative stress in incipient stages of atherosclerosis probably diminishes stimuli leading to monocyte recruitment and formation of macrophage-derived FCs. NAC was also found to inhibit the chemotactic and invasive activities of human tumor cells, most likely through inhibition of gelatinase activity, and it is currently considered to be a promising antioxidant and anticancer chemopreventive agent. Our study shows a new potential use for NAC as an inhibitor of MMP activity. Inhibition of MMP activity by antioxidants early in the course of atherosclerotic lesion development may limit inflammatory cell infiltration, cell movement, and proliferation, events that all require participation of active MMPs. Importantly, by showing the possibility of inhibiting the matrix-degrading capacity of macrophage FCs prevailing in advanced plaques, the present results suggest that treatment with ROS scavengers may be effective in late stages of atherosclerosis. This would contribute to restricting the weakening of vascular matrix, thought to be a major factor precipitating plaque destabilization. Although we extensively examined and report here the effects of NAC, we believe that the results are applicable to other antioxidants, such as vitamin E and probucol, as suggested by our preliminary experiments. Future in vivo experiments need to

Figure 6. NAC treatment abolishes gelatinolytic activity and decreases MMP-9 protein level released in vitro by aortic lesion explants. Aortic segments were maintained in culture for up to 4 days with or without NAC. A, Gelatinolytic activity released by tissue explants of abdominal or thoracic aorta of hypercholesterolemic rabbits in an experiment in which aortic explants were treated with 10 mmol/L for 24 hours (loading of all lanes was normalized by protein). B, NAC treatment significantly diminished MMP-9 protein level released by aortic explants, detected by immunoblotting of culture media conditioned by segments of aortic arch, thoracic, and abdominal atherosclerotic aorta. Tissues were incubated in presence (+) or absence (−) of 10 mmol/L NAC for 24 hours. Bars represent average values obtained by normalizing signal of culture media conditioned by treated tissues to those of control (untreated, −) specimens ±SEM in 4 independent experiments. *P<0.05, **P<0.01.

MMP-9 are also interesting. For instance, we found that NAC treatment effectively inhibited the level of MMP-9 protein secreted in culture by macrophages. Findings from in situ observations of macrophage-derived FCs of NAC-treated experimental atheroma support NAC inhibition of MMP-9 expression. The hypothesis that redox stress modulates cellular MMP-9 expression is novel; thus, at present, the mechanism is still unknown. Possibly relevant information is provided by studies showing MMP-9 induction by cytokines and phorbol esters in a variety of cells, including vascular
be undertaken to confirm the possibility of using antioxidant therapy as a way to improve the stability of atherosclerotic plaques.

Acknowledgments
This study was supported through funds provided by a Grant-in-Aid from the American Heart Association and a faculty development award from the Beda Whitaker Foundation.

References
1. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. *Atherosclerosis*. 1991;87:87–90.
3. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation*. 1994;89:36–44.


N-Acetyl-Cysteine Decreases the Matrix-Degrading Capacity of Macrophage-Derived Foam Cells: New Target for Antioxidant Therapy?
Zorina S. Galis, Kazuhiko Asanuma, Denis Godin and Xiaoping Meng

*Circulation*. 1998;97:2445-2453
doi: 10.1161/01.CIR.97.24.2445

*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1998 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/97/24/2445

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation* is online at:
http://circ.ahajournals.org/subscriptions/